M A Valdovinos-Díaz, F A Félix-Téllez, M A Vargas-Martínez, J Jiménez-Pavón, J Aquino-Matus, J S Arenas-Martínez, J M Remes-Troche, E Coss-Adame, O Gómez-Escudero, K R García-Zermeño, C P Gyawali, M Amieva-Balmori, G Vázquez-Elizondo, A S Villar-Chávez, L R Valdovinos-García, M Mejía-Rivas, P C Gómez-Castaños
Journal: Revista de gastroenterologia de Mexico (English) 2025;90(2):252-287
PMID: 40374462
Disorders of gut-brain interaction (DGBI) are characterized by alterations in both central and peripheral gut-brain axis (GBA)-related stimuli, and include esophageal, gastroduodenal, intestinal and anorectal disorders. Despite the fact that several pathophysiologic mechanisms are involved, the mainstay of treatment is neuromodulators, a heterogeneous group of drugs that act on pathways related to central and peripheral pain processing. This expert review by both the AMG (Asociación Mexicana de Gastroenterología) and AMNM (Asociación Mexicana de Neurogastroenterología y Motilidad) summarizes a series of updated clinical recommendations based on an exhaustive review of the literature, regarding the use of neuromodulators for DGBI, and is grouped into six sections: pharmacologic principles, definition, classification, mechanism of action, indications and use in each DGBI subtype, up/downscaling strategies, combination therapy, adverse events, joint use along with psychiatry in the case of comorbidities, and non-pharmacologic neuromodulation. Furthermore, drug selection process tips and dose personalization according to individual groups and sensitivities are provided, and special cases with DGBI-psychiatric comorbidity, as well as overlap with another DGBI, are considered.
Copyright © 2025 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All rights reserved.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.